Cover Image
市場調查報告書

血脂異常症治療藥的全球市場 - 2015∼2023年:Statin,膽酸結合樹脂,纖維酸,Omega-3脂肪酸衍生物,菸鹼酸 - 產業分析,市場規模,市場佔有率,成長性,市場趨勢,未來預測

Dyslipidemia Drugs Market: (By Drug Class - Statins, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 338033
出版日期 內容資訊 英文 101 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血脂異常症治療藥的全球市場 - 2015∼2023年:Statin,膽酸結合樹脂,纖維酸,Omega-3脂肪酸衍生物,菸鹼酸 - 產業分析,市場規模,市場佔有率,成長性,市場趨勢,未來預測 Dyslipidemia Drugs Market: (By Drug Class - Statins, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
出版日期: 2015年08月05日 內容資訊: 英文 101 Pages
簡介

本報告詳查血脂異常症治療藥的全球市場,提供您由各種角度來概括性驗証推動市場成長要素,阻礙因素,市場機會,市場吸引力,市場競爭情形等,同時更提供目前市場方案分析與2015年到2023年的市場預測。

第1章 序論

  • 關於本報告
  • 市場分類
  • 調查手法
  • 簡稱一覽

第2章 摘要整理

  • 市場簡介:血脂異常症治療藥市場 - 2014年及2023年
  • 各類藥物來看的血脂異常症治療藥市場 - 2014年
    • 比較分析:從各地區來看血脂異常症治療藥市場 - 2014年及2023年

第3章 市場概況

  • 概要
  • 流行病學的分析:血脂異常症
  • 血脂異常症的病因
    • 主原因 (血脂異常症的遺傳原因)
    • 次級原因 (生活習慣上的要素)
  • 血脂異常症的診斷
    • 血清脂質濃度檢測 (總膽固醇,HDL,LDL,VLDL等)
    • 其他檢驗 (脂蛋白檢驗,載脂蛋白-B檢驗等)
    • 次級原因的篩檢與診斷
  • 血脂異常症治療趨勢及未來願景 (案例:PCSK9,CETP抑制劑等)
  • 市場動態
    • 推動市場成長要素
      • 由於膽固醇及三酸甘油酯脂質異常的人口全球性增加促進市場成長
      • 由於肥胖及糖尿病患者人口增加預測血脂異常症數量也將增大,其治療藥的需求將增加
      • 大範圍研究開發帶來了血脂異常症治療藥的戲劇性轉戾點
      • 透過廣宣活動提升對血脂異常症的認識
    • 阻礙市場成長要素
      • 專利到期逼近,淨利率銳減
      • 新血脂異常症治療藥已停產
    • 市場機會
      • 在新興各國的商圈擴大讓銷售量得以擴大
      • 血脂異常症的生物治療藥
      • 新類血脂異常症治療藥群的藥物分子開發促進市場成長
      • 新開發新藥用策略性合作
  • 市場魅力分析:從各地區來看血脂異常症治療藥市場
  • 血脂異常症治療藥全球市場的主要企業的市場佔有率 - 2014年
    • 各企業來看的血脂異常症治療藥全球市場的市場佔有率分析 - 2014年

第4章 就各藥物類型來看的血脂異常症治療藥市場

  • 序論
    • 就各藥物類型來看血脂異常症治療藥市場收益額 - 2013∼2023年
  • Statin
    • Statin市場收益額 - 2013∼2023年
  • 膽酸結合樹脂 (Cholestyramine, Colestipol, Colesevelam等)
    • 膽酸結合樹脂市場收益額 - 2013∼2023年
  • 纖維酸及Omega-3脂肪酸衍生物 (Fenofibrate, Gemfibrozil, Vascespa等)
    • 纖維酸及Omega-3脂肪酸衍生物市場收益額 - 2013∼2023年
  • 菸鹼酸 (Niacor,Niaspan,Slo-Niacin等)
    • 菸鹼酸市場收益額 - 2013∼2023年
  • 其他 (Combination drugs such as lovastatin and niacin, atorvastatin and amlodipine, simvastatin and ezetimibe, cholesterol absorption inhibitors等)
    • 其他的醫藥品市場收益額 - 2013∼2023年
  • 研究開發平台上的藥物
    • 就各藥物類型來看的開發平台階段醫藥品的血脂異常症治療藥收益額 - 2013∼2023年
    • anasetorapibu (MK-0859)
      • anasetorapibu市場收益額 - 2018∼2023年
    • Evacetrapib (LY2484595)
      • Evacetrapib市場收益額 - 2017∼2023年
    • Praluent (Alirocumab)
      • Praluent市場收益額 - 2015∼2023年
    • Evolocumab (Repatha)
      • Evolocumab市場收益額 - 2015∼2023年
    • Bococizumab (RN316)
      • Bococizumab市場收益額 - 2019∼2023年

第5章 從各地區來看血脂異常症治療藥市場

  • 概要
    • 從各地區來看血脂異常症治療藥市場收益額 - 2013∼2021年
  • 北美
    • 血脂異常症治療藥北美市場各國收益額 - 2013∼2023年
  • 歐洲
    • 血脂異常症治療藥歐洲市場各國收益額 - 2013∼2023年
  • 亞太地區
    • 血脂異常症治療藥亞太地區市場各國收益額 - 2013∼2023年
  • 南美
    • 血脂異常症治療藥南美市場各國收益額 - 2013∼2023年
  • 中東及非洲地區
    • 中東及非洲地區的血脂異常症治療藥市場各國收益額 - 2013∼2023年

第6章 建議

  • 開發血脂異常症治療用組合型治療藥
  • 主要的藥物開發企業是否需要藉由與醫院合作或是企業收購來開發有效果的血脂異常症治療藥
  • 全球性企業應以低到中所得國家為目標,來擴大收益

第7章 主要企業簡介

  • Abbott Laboratories
    • 公司概要
    • 財務狀況
    • 產品系列
    • 商務策略
    • 最近的企業發展
  • AstraZeneca plc
  • Amgen, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Mylan N.V.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • 鹽野義製藥
  • 武田藥品工業
  • Teva Pharmaceutical Industries Ltd.
目錄

Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers due to increasing demand and prescriptions of these medications. According to the Centers for Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions such as North America and Europe. Moreover, several articles published in open journals stated that demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However, loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the growth of the market during the forecast period.

This report comprises a detailed study of various drug classes for the treatment of dyslipidemia. The dyslipidemia drugs market has been segmented into statins, bile acid resins, fibric acid derivatives, niacins, and others (combination drugs and cholesterol absorption inhibitors). The statins segment comprises combined market revenue of statin drugs such as atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin, and lovastatin. The bile acid resins segment included resins such as Cholestyramine, Colestipol, Colesevelam, and Cholybar. The fibric acid, and omega-3 fatty acid derivatives segment comprises generic drugs such as Fenofibrate, Clofibrate, and Bezafibrate. Other branded omega-3 fatty acids include Lovaza, Vascespa, and Omtryg. Niacins includes drugs such as Niaspan, Slo-Niacin, and Niacor. The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs. The market size and forecast for each drug class has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (% CAGR) for the forecast period from 2015 to 2023 for each drug class, considering 2013 to 2014 as the historical and base year, respectively.

By geography, the dyslipidemia drugs market has been studied for five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Each region has been further divided into major countries i.e., North America: the U.S. and Canada; Europe: Germany, France, the U.K. and Rest of Europe; Asia Pacific: China, Japan, India and Rest of APAC; Latin America: Brazil and Rest of LATAM; Middle East and Africa: South Africa and Rest of MEA. The market size and forecast for each region and country has been estimated for the period 2013 to 2023 in terms of revenue (USD million). The report also provides the compound annual growth rate (CAGR %) during the forecast period from 2015 to 2023 for all the regions and countries mentioned above.

The market overview section of the report discusses the market dynamics with respect to the market drivers, restraints, and opportunities. This section also covers information on epidemiology, etiology, dyslipidemia diagnostics, trends and future aspects, and market attractiveness analysis, by geography of the dyslipidemia drugs market. A list of recommendations for existing and new players to enter the market and enhance their position is also provided in the report. The report concludes with company profiles of key players operating in various drug classes of the market. Each company profile includes business overview, financial overview, product portfolio, business strategies, and recent developments of the respective market player. Prominent players in the dyslipidemia drugs market that have been profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., and AstraZeneca plc

The global dyslipidemia drugs market is segmented as follows:

Global Dyslipidemia Drugs Market, by Drug Class

  • Statins
  • Bile Acid Resins
  • Fibric Acid and Omega-3 Fatty Acid Derivatives
  • Niacins
  • Others (Combination Drugs and Cholesterol Absorption Inhibitors)

Global Dyslipidemia Drugs Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Sources
      • 1.3.1.1. Secondary Research
      • 1.3.1.2. Primary Research
      • 1.3.1.3. Assumption
  • 1.4. List of Abbreviations

Chapter 2 - Executive Summary

  • 2.1. Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
  • 2.2. Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
    • 2.2.1 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)

Chapter 3 - Market Overview

  • 3.1. Overview
  • 3.2. Epidemiology: Dyslipidemia
  • 3.3. Etiology of Dyslipidemia
    • 3.3.1. Primary Causes (genetic causes of dyslipidemia)
    • 3.3.2. Secondary Causes (lifestyle factors)
  • 3.4. Dyslipidemia Diagnostics
    • 3.4.1. Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc.)
    • 3.4.2. Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc.)
    • 3.4.3. Secondary Causes Screening and Diagnostics
  • 3.5. Trends and Future Aspects in Dyslipidemia Therapeutics (e.g. PCSK9, CETP inhibitors, etc.)
  • 3.6. Market Dynamics
    • 3.6.1. Market Drivers
      • 3.6.1.1. Global increasing prevalence of population with cholesterol and triglyceride abnormalities expected to propel the market
      • 3.6.1.2. Rise in obese and diabetic populations is expected to increase the incidence of dyslipidemia, and thus demand for dyslipidemia drugs
      • 3.6.1.3. Extensive research and development changes bring turnaround changes in the dyslipidemia drugs market
      • 3.6.1.4. Rising disease awareness through promotional activities
    • 3.6.2. Market Restraints
      • 3.6.2.1. Impending patent expirations to deplete profit margins
      • 3.6.2.2. Discontinuation of novel dyslipidemia drugs
    • 3.6.3. Opportunities
      • 3.6.3.1. Expanding footprint in emerging nations to generate high sales growth
      • 3.6.3.2. Biological therapies for the treatment of dyslipidemia
      • 3.6.3.3. Development of molecules from newer class of dyslipidemia drugs provide a ladder for growth
      • 3.6.3.4. Strategic collaborations for new drug development
  • 3.7. Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
  • 3.8. Market Share by Key Players of Global Dyslipidemia Drugs Market, 2014 (Value %)
    • 3.8.1. Global Dyslipidemia Drugs Market Share Analysis, by Key Players, 2014 (%)

Chapter 4 - Dyslipidemia Drugs Market, by Drug Class

  • 4.1. Introduction
    • 4.1.1. Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 - 2023 (USD Million)
  • 4.2. Statins
    • 4.2.1. Statins Market Revenue, 2013 - 2023 (USD Million)
  • 4.3. Bile Acid Resins (Cholestyramine, Colestipol, Colesevelam, etc.)
    • 4.3.1. Bile Acid Resins Market Revenue, 2013 - 2023 (USD Million)
  • 4.4. Fibric Acid and Omega-3 Fatty Acid Derivatives (Fenofibrate, Gemfibrozil, Vascespa, etc.)
    • 4.4.1. Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 - 2023 (USD Million)
  • 4.5. Niacins (Niacor, Niaspan, Slo-Niacin, etc.)
    • 4.5.1. Niacins Market Revenue, 2013 - 2023 (USD Million)
  • 4.6. Others (Combination drugs such as lovastatin and niacin, atorvastatin and amlodipine, simvastatin and ezetimibe, cholesterol absorption inhibitors, etc.)
    • 4.6.1. Others Market Revenue, 2013 - 2023 (USD Million)
  • 4.7. Pipeline Drugs
    • 4.7.1. Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 - 2023 (USD Million)
    • 4.7.2. Anacetrapib (MK-0859)
      • 4.7.2.1. Anacetrapib Market Revenue, 2018 - 2023 (USD Million)
    • 4.7.3. Evacetrapib (LY2484595)
      • 4.7.3.1. Evacetrapib Market Revenue, 2017 - 2023 (USD Million)
    • 4.7.4. Praluent (Alirocumab)
      • 4.7.4.1. Praluent Market Revenue, 2015 - 2023 (USD Million)
    • 4.7.5. Evolocumab (Repatha)
      • 4.7.5.1. Evolocumab Market Revenue, 2015 - 2023 (USD Million)
    • 4.7.6. Bococizumab (RN316)
      • 4.7.6.1. Bococizumab Market Revenue, 2019 - 2023 (USD Million)

Chapter 5 - Dyslipidemia Drugs Market, by Geography

  • 5.1. Overview
    • 5.1.1. Dyslipidemia Drugs Market Revenue, by Geography, 2013 - 2023 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)

Chapter 6 - Recommendations

  • 6.1. Developing combination drugs for the treatment of dyslipidemia
  • 6.2. Major research-based drug developing companies must collaborate with hospitals or acquire pharma establishments to develop more effective dyslipidemia treatments
  • 6.3. Global players should target low to medium income countries to generate higher revenues

Chapter 7 - Company Profiles

  • 7.1. Abbott Laboratories
    • 7.1.1. Company Overview
    • 7.1.2. Financial Overview
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategies
    • 7.1.5. Recent Developments
  • 7.2. AstraZeneca plc
    • 7.2.1. Company Overview
    • 7.2.2. Financial Overview
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategies
    • 7.2.5. Recent Developments
  • 7.3. Amgen, Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Financial Overview
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategies
    • 7.3.5. Recent Developments
  • 7.4. Bayer AG
    • 7.4.1. Company Overview
    • 7.4.2. Financial Overview
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategies
    • 7.4.5. Recent Developments
  • 7.5. Bristol-Myers Squibb Company
    • 7.5.1. Company Overview
    • 7.5.2. Financial Overview
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategies
    • 7.5.5. Recent Developments
  • 7.6. Mylan N.V.
    • 7.6.1. Company Overview
    • 7.6.2. Financial Overview
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategies
    • 7.6.5. Recent Developments
  • 7.7. Novartis AG
    • 7.7.1. Company Overview
    • 7.7.2. Financial Overview
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategies
    • 7.7.5. Recent Developments
  • 7.8. Merck & Co., Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Financial Overview
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategies
    • 7.8.5. Recent Developments
  • 7.9. Pfizer, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Financial Overview
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategies
    • 7.9.5. Recent Developments
  • 7.10. Shionogi & Co., Ltd.
    • 7.10.1. Company Overview
    • 7.10.2. Financial Overview
    • 7.10.3. Product Portfolio
    • 7.10.4. Business Strategies
    • 7.10.5. Recent Developments
  • 7.11. Takeda Pharmaceutical Company Limited
    • 7.11.1. Company Overview
    • 7.11.2. Financial Overview
    • 7.11.3. Product Portfolio
    • 7.11.4. Business Strategies
    • 7.11.5. Recent Developments
  • 7.12. Teva Pharmaceutical Industries Ltd.
    • 7.12.1. Company Overview
    • 7.12.2. Financial Overview
    • 7.12.3. Product Portfolio
    • 7.12.4. Business Strategies
    • 7.12.5. Recent Developments

List of Figures

  • FIG. 1: Dyslipidemia Drugs Market: Market Segmentation
  • FIG. 2: Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
  • FIG. 3: Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)
  • FIG. 4: Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
  • FIG. 5: Global Dyslipidemia Drugs Market: Market Share, by Key Players, 2014 (%)
  • FIG. 6: Statins Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 7: Bile Acid Resins Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 8: Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 9: Niacins Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 10: Others Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 11: Anacetrapib Market Revenue, 2018 - 2023 (USD Million)
  • FIG. 12: Evacetrapib Market Revenue, 2017 - 2023 (USD Million)
  • FIG. 13: Praluent Market Revenue, 2015 - 2023 (USD Million)
  • FIG. 14: Evolocumab Market Revenue, 2015 - 2023 (USD Million)
  • FIG. 15: Bococizumab Market Revenue, 2019 - 2023 (USD Million)
  • FIG. 16: Abbott Laboratories: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 17: AstraZeneca plc: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 18: Amgen, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 19: Bayer AG: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 20: Bristol-Myers Squibb Company: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 21: Mylan N.V.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 22: Novartis AG: Annual Revenues, 2012 - 2014 (USD Million)
  • FIG. 23: Merck & Co., Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 24: Pfizer, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 25: Shionogi & Co., Ltd.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 26: Takeda Pharmaceutical Company Limited: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 27: Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 - 2014 (USD Million)

List of Tables

  • TABLE 1: List of Abbreviations
  • TABLE 2: Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
  • TABLE 3: Number of People with Diabetes (20 Years - 79 years), by Country/Territory, 2013 (Millions)
  • TABLE 4: Impact Analysis of Market Drivers
  • TABLE 5: Impact Analysis of Market Restraints
  • TABLE 6: Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 - 2023 (USD Million)
  • TABLE 7: Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 - 2023 (USD Million)
  • TABLE 8: Dyslipidemia Drugs Market Revenue, by Geography, 2013 - 2023 (USD Million)
  • TABLE 9: North America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 10: Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 11: Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 12: Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 13: Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
Back to Top